The six peptides an FDA panel backed for compounding

The votes

Vote counts are as reported by trade press (AJMC, PharmTech); FDA had not posted a vote summary we could find. Semax and epitalon passed by margins AJMC called similarly tight, without counts.

What the vote means, and what it doesn't

• It is advice, not a decision. The committee's votes are not binding. FDA decides whether to add any of these peptides to the 503A bulks list.
• Nothing has changed yet. None of the six is on the 503A bulks list, so pharmacies still may not compound them under that law, and none is an FDA-approved drug.
• It isn't an approval, even if FDA agrees. Being on the bulks list would let a licensed pharmacy compound the peptide for an individual patient with a prescription. It would not make it an approved medicine or show that it works.
• It doesn't cover research vials. Peptides sold online "for research use only" are a separate market; the vote says nothing about their purity or safety.
• The human evidence is thin. FDA's briefing documents found little or no human safety data for these peptides. For KPV it found none at all.

What happens next

• FDA review. FDA must decide whether to accept the recommendations. It has gone against its advisory committees before.
• Rulemaking. If FDA agrees, adding a substance to the 503A bulks list goes through notice-and-comment rulemaking, which takes months. No proposed rule had been published when we last checked.
• A possible stopgap. On October 7, 2026, the Washington Post reported, citing two unnamed people, that the administration is preparing a temporary measure to let some compounding pharmacies sell certain restricted peptides while rules are written. It had not been announced, HHS did not comment, and which peptides it would cover was not reported.

We update this page and the regulatory tracker when FDA acts.

Our video on each peptide

What the research on each of the six actually shows, from its studies and FDA's briefing documents.

▶2:47

Video overview · 2:47

BPC-157: What the Research Actually Shows (Rats vs. People)

Where it comes from, how it might work, what the rat and cell studies found, how little human data exists, the one registered human trial, and its safety and legal status.

Narrated with an AI voice from its profile's sources; education only, no dosing. Read the full page → · Watch on YouTube ↗

▶3:04

Video overview · 3:04

KPV Peptide: Gut Inflammation, Skin and the FDA Vote. What the Research Shows

Where the three-amino-acid KPV fragment comes from, how it acts in cells, the mouse colitis studies, why it has never been tested in people, and its FDA, compounding and anti-doping status.

Narrated with an AI voice from its profile's sources; education only, no dosing. Read the full page → · Watch on YouTube ↗

▶3:30

Video overview · 3:30

TB-500: What the Research Actually Shows (and Why It Isn't Thymosin Beta-4)

How TB-500 differs from the natural protein thymosin beta-4, what the rat and cell studies found, why the only human trials tested the full protein, and its safety, FDA and anti-doping status.

Narrated with an AI voice from its profile's sources; education only, no dosing. Read the full page → · Watch on YouTube ↗

▶2:44

Video overview · 2:44

MOTS-c: Is It Really "Exercise in a Pill"? What the Research Shows

Where the mitochondrial peptide comes from, how it acts on the cell's energy sensor, the mouse studies behind the hype, why no published study has given it to people, and its FDA, compounding and anti-doping status.

Narrated with an AI voice from its profile's sources; education only, no dosing. Read the full page → · Watch on YouTube ↗

▶2:47

Video overview · 2:47

Semax vs Selank: Do These Russian "Brain Peptides" Actually Work? (The Evidence)

What each peptide is, the rat brain studies behind the memory claim, the small Russian stroke and anxiety studies, why no placebo-controlled trial has tested memory or focus in healthy people, and their FDA and anti-doping status.

Narrated with an AI voice from its profile's sources; education only, no dosing. Read the full page → · Watch on YouTube ↗

▶3:24

Video overview · 3:24

Epitalon: Does It Really Lengthen Telomeres and Extend Lifespan? What the Research Shows

How epitalon differs from the pineal extract epithalamin, the cell studies behind the telomere claim, the mixed animal lifespan results, why no published study has measured telomeres or lifespan in people given it, and its FDA, compounding and anti-doping status.

Narrated with an AI voice from its profile's sources; education only, no dosing. Read the full page → · Watch on YouTube ↗

Sources

• FDA Pharmacy Compounding Advisory Committee, July 23–24, 2026 (meeting page and briefing documents)
• AJMC: FDA Panel Backs 6 Peptides for Compounding (July 31, 2026)
• PharmTech: Peptide Compounding Vote Raises New Questions for Drug Developers
• NCPA: FDA advisory committee nominates six peptides for pharmacies to compound (July 31, 2026)
• RAPS: FDA advisory committee backs two controversial peptides (July 23, 2026)
• Becker's Hospital Review on the Washington Post's October 7, 2026 stopgap report

Compiled with AI assistance from the sources above. Not legal or medical advice; confirm with the source before relying on a status.